Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 Inhibitors

Full text
Author(s):
Show less -
Kavanagh, Madeline E. [1] ; Coyne, Anthony G. [1] ; McLean, Kirsty J. [2] ; James, Guy G. [1] ; Levy, Colin W. [2] ; Marino, Leonardo B. [3, 4] ; de Carvalho, Luiz Pedro S. [3] ; Chan, Daniel S. H. [1] ; Hudson, Sean A. [1, 5] ; Surade, Sachin [6] ; Leys, David [2] ; Munro, Andrew W. [2] ; Abell, Chris [1]
Total Authors: 13
Affiliation:
[1] Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW - England
[2] Univ Manchester, Ctr Synthet Biol Fine & Specialty Chem SYNBIOCHEM, Manchester Inst Biotechnol, Fac Life Sci, 131 Princess St, Manchester M1 7DN, Lancs - England
[3] Francis Crick Inst, Mill Hill Lab, Lab Mycobacterial Metab & Antibiot Res, London NW7 1AA - England
[4] Sao Paulo State Univ UNESP, Sch Pharmaceut Sci, BR-4801902 Araraquara, SP - Brazil
[5] Australian Natl Univ, Res Sch Chem, Coll Phys & Math Sci, Bldg 137, Sullivans Creek Rd, Canberra, ACT 0200 - Australia
[6] Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA - England
Total Affiliations: 6
Document type: Journal article
Source: Journal of Medicinal Chemistry; v. 59, n. 7, p. 3272-3302, APR 14 2016.
Web of Science Citations: 23
Abstract

The essential enzyme CYP121 is a target for drug development against antibiotic resistant strains of Mycobacterium tuberculosis. A triazol-1-yl phenol fragment 1 was identified to bind to CYP121 using a cascade of biophysical assays. Synthetic merging and optimization of 1 produced a 100-fold improvement in binding affinity, yielding lead compound 2 (K-D = 15 mu M). Deconstruction of 2 into its component retrofragments allowed the group efficiency of structural motifs to be assessed, the identification of more LE scaffolds for optimization and highlighted binding affinity hotspots. Structure-guided addition of a metal-binding pharmacophore onto LE retrofragment scaffolds produced low nanomolar (K-D = 15 nM) CYP121 ligands. Elaboration of these compounds to target binding hotspots in the distal active site afforded compounds with excellent selectivity against human drug-metabolizing P450s. Analysis of the factors governing ligand potency and selectivity using X-ray crystallography, UV-vis spectroscopy, and native mass spectrometry provides insight for subsequent drug development. (AU)

FAPESP's process: 11/21232-1 - Evaluation of the involvement of eIF5A in the secretory pathway in Saccharomyces cerevisiae
Grantee:Leonardo Biancolino Marino
Support Opportunities: Scholarships in Brazil - Doctorate (Direct)